Antibody Drug Conjugate Business Operations: A Pharma CEO’s ADC Playbook

Antibody-drug conjugates have moved from a promising but technically difficult drug class to one of oncology’s most competitive and commercially successful categories. For the pharma CEO, managing ADC operations requires mastering a manufacturing complexity unlike most other biologics, navigating a crowded oncology competitive landscape, designing clinical programs that establish differentiation, and building commercial infrastructure for oncology indications with significant unmet need. This guide provides a comprehensive operational framework for pharma CEOs leading ADC programs.

The ADC Operating Environment

ADCs are targeted cancer therapies that combine the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy payloads, linked by a chemical linker that determines stability and release characteristics. The combination of these three components, each with its own manufacturing and quality requirements, creates a product that is more complex to manufacture than either conventional antibodies or small molecule chemotherapy agents.

The commercial success of ADCs including trastuzumab deruxtecan and sacituzumab govitecan has validated the class and triggered a wave of investment that has made ADC development one of the most competitive areas in oncology. Pharma CEOs entering or expanding in the ADC space face a landscape where differentiation is increasingly difficult and where operational execution quality can determine competitive outcomes.

The regulatory environment for ADCs reflects both their biological complexity and their cytotoxic payload risk. ADCs are regulated as biologics, with full biologics license application (BLA) requirements, but also carry the manufacturing and safety requirements associated with their toxic payloads. Occupational safety during manufacturing is a genuine operational concern that distinguishes ADC operations from conventional antibody manufacturing.

ADC Manufacturing Operations

Manufacturing is the most distinctive operational challenge in ADC programs. The complexity of combining three distinct components, each with its own quality requirements, creates manufacturing risk that must be managed throughout development and commercial supply.

Antibody manufacturing. The antibody component of an ADC is manufactured using conventional mammalian cell culture, typically in Chinese hamster ovary cells, and purified through chromatography. While antibody manufacturing is well-understood as a process, the antibody used in an ADC must have specific characteristics that support conjugation, including defined conjugation sites and minimal glycosylation variation that could affect linker attachment.

Payload synthesis. ADC payloads are typically highly potent small molecules, including auristatins, maytansinoids, or topoisomerase inhibitors, that are synthesized through organic chemistry processes. The high potency of these payloads, many are active at sub-nanomolar concentrations, creates occupational safety requirements for manufacturing personnel that are substantially more demanding than for conventional pharmaceutical synthesis. CEOs must invest in containment facilities and personnel protection programs that exceed standard pharmaceutical manufacturing standards.

Conjugation and formulation. The conjugation step, where the linker-payload is attached to the antibody, is the most technically distinctive step in ADC manufacturing. Conjugation chemistry must be precisely controlled to achieve consistent drug-to-antibody ratio (DAR), a critical quality attribute that affects both efficacy and safety. CEOs should prioritize process development investment in conjugation chemistry, as DAR variability is a common source of clinical and regulatory risk.

Drug-to-antibody ratio control. The DAR of an ADC product determines its potency and its therapeutic window. Higher DAR products are more potent but may be less stable and more toxic. Conventional ADCs have average DARs of 2 to 4; newer site-specific conjugation technologies allow more precise DAR control. CEOs investing in ADC platforms should evaluate whether site-specific conjugation technology is appropriate for their programs given its potential quality and clinical advantages.

CDMO selection and management. Most ADC companies, including large pharmaceutical companies, rely on CDMOs for at least some components of ADC manufacturing. The specialized nature of payload synthesis and high-potency manufacturing means that the CDMO landscape is more limited than for conventional biologics. CEOs should identify and qualify ADC manufacturing partners early, before supply becomes urgent, and establish strong quality oversight relationships with their CDMOs.

Oncology Clinical Program Design

ADC clinical programs operate within the broader oncology development environment, which has both well-established conventions and rapidly evolving norms driven by the success of immunotherapy and targeted therapy.

Target selection and antigen validation. The antibody target determines the patient population that can potentially benefit from the ADC. Target selection requires both biological rationale for the antigen’s role in the cancer and evidence that the antigen is expressed on tumor cells in a relevant patient population. Companion diagnostic development, which confirms antigen expression in individual patients, is often a necessary part of ADC clinical programs.

Indication selection strategy. ADCs can potentially be developed across a wide range of oncology indications. CEOs must make strategic decisions about which indications to pursue first, balancing scientific rationale, patient population size, competitive landscape, and development speed. First indications should be those where the ADC’s mechanism offers the clearest clinical advantage over existing therapies and where development risk is manageable.

Clinical trial design. ADC clinical programs typically move from dose escalation in heavily pre-treated patients to registration trials in earlier lines of therapy as the safety profile is established. CEOs should ensure their clinical program design anticipates the regulatory requirements for registration while generating the differentiation data needed for commercial success. Basket trials that evaluate an ADC across multiple tumor types sharing the target antigen can accelerate development but require careful statistical design.

Combination strategies. The most important near-term opportunity in ADC development is combination with checkpoint inhibitors and other immuno-oncology agents. Clinical programs that establish synergistic combinations early can significantly expand addressable patient populations. CEOs should invest in combination studies alongside single-agent development and build relationships with immuno-oncology companies for combination trial collaboration.

Biomarker strategy. Identifying biomarkers that predict ADC response is both a scientific challenge and a commercial opportunity. Companion diagnostics that identify patients most likely to respond allow for more targeted use of ADCs and can support premium pricing. CEOs should invest in biomarker development as an integral part of the clinical program, not as an afterthought.

For context on managing broader pharma clinical operations, see this clinical trials ops resource.

Competitive Market Positioning

The ADC market has become intensely competitive, with dozens of programs in development across major oncology indications. CEOs must develop clear competitive positioning strategies.

Payload differentiation. The choice of payload is a key differentiator among ADCs. Auristatin payloads (MMAE, MMAF) are well-established but widely used. Topoisomerase I inhibitors have achieved spectacular clinical results with agents like trastuzumab deruxtecan. Novel payloads including RNA polymerase inhibitors, kinase inhibitors, and immune stimulants offer potential for differentiation. CEOs should evaluate payload innovation as a strategic priority.

Linker technology. Linker stability and release mechanism are critical to ADC performance. Cleavable linkers that release payload in the tumor microenvironment offer efficacy advantages through the bystander effect but raise payload release concerns in circulation. Stable linkers reduce premature payload release but require intracellular processing for payload release. Novel linker technologies are an active area of innovation and a potential source of competitive differentiation.

Target landscape analysis. With dozens of ADCs in development, some antigen targets are already heavily congested. CEOs should conduct rigorous competitive landscape analysis before committing to target programs, assessing the number of competing programs, their clinical stage, and their clinical results. Novel targets with strong scientific rationale but fewer competitors offer better strategic positioning.

Next-generation ADC platform development. CEOs leading ADC programs should invest in next-generation ADC platform capabilities including site-specific conjugation, bispecific antibody formats, dual payload systems, and novel delivery mechanisms. Platform investment creates a pipeline of future products and proprietary technology that provides competitive advantage beyond individual product programs.

Commercial Operations for ADC Products

Commercial operations for approved ADC products share characteristics with oncology specialty pharmaceuticals generally but have ADC-specific elements related to toxicity management and patient selection.

Oncology commercial infrastructure. ADC products are sold through oncology-focused commercial teams with deep relationships with medical oncologists, tumor boards, and academic cancer centers. CEOs building commercial infrastructure for ADC products should focus on hiring oncology-experienced commercial talent and building relationships with key opinion leaders in the target indication early in clinical development.

Toxicity education. ADCs have toxicity profiles that include both antibody-class effects and payload-related toxicities. Interstitial lung disease has emerged as a class effect for topoisomerase I inhibitor ADCs. CEOs must ensure that medical affairs and commercial teams provide comprehensive toxicity education to treating physicians, including clear guidance on monitoring, dose modification, and treatment discontinuation criteria. Toxicity management that preserves time on treatment is both clinically and commercially important.

Managed care and market access. ADC products are subject to the full range of managed care contracting challenges that face oncology specialty pharmaceuticals. CEOs should build market access operations that address payer utilization management, step therapy requirements, and prior authorization criteria. Health economic modeling that demonstrates ADC value relative to existing therapies is an important element of market access strategy.

Real-world evidence generation. Post-marketing, real-world evidence programs that track ADC outcomes in broader patient populations than clinical trials can both support label expansion efforts and provide evidence for payer negotiations. CEOs should plan real-world evidence programs as part of the commercial launch strategy rather than as afterthoughts.

According to McKinsey, ADC programs that invest in manufacturing process development early and build differentiated payloads or linker technologies are positioned to achieve commercial success in an increasingly competitive market.

Regulatory Strategy for ADC Programs

Regulatory strategy for ADC programs must account for both the biologic regulatory framework and the unique aspects of ADC pharmacology and manufacturing.

BLA submission strategy. ADC BLAs must include comprehensive characterization of the antibody, linker-payload, and conjugated product as well as manufacturing process validation data. The complexity of the ADC molecular structure means that CMC packages for ADC BLAs are substantially more complex than for conventional antibodies. CEOs should plan for longer BLA preparation timelines and ensure adequate resourcing for CMC submission preparation.

Accelerated approval opportunities. Many ADC programs in oncology are eligible for Accelerated Approval based on surrogate endpoints such as objective response rate or progression-free survival. CEOs should pursue accelerated approval where appropriate, as it reduces time to market and provides valuable commercial revenue during the confirmatory trial period.

Pediatric considerations. FDA requirements for pediatric development apply to ADC programs in oncology. CEOs should address pediatric development planning early in the regulatory strategy to avoid late-stage surprises that could affect approval timelines.

Global regulatory strategy. ADC development is a global enterprise, with clinical trials conducted across multiple regions and commercial launches planned for major markets including Europe, Japan, and China. CEOs should develop global regulatory strategies that leverage clinical data efficiently across regions and anticipate the specific requirements of each major regulatory authority.

Alliance and Partnership Operations

Given the capital requirements and technical complexity of ADC development, many companies pursue alliance and partnership strategies for ADC programs.

In-licensing strategy. Companies that lack internal ADC capabilities often in-license ADC programs from academic institutions, biotech companies, or platform companies. CEOs should evaluate in-licensing opportunities with a rigorous assessment of the target biology, clinical data package, manufacturing readiness, and competitive landscape.

Collaboration structures. ADC collaborations between large pharma and biotech frequently involve licensing of ADC technology platforms, co-development arrangements, and profit-sharing or royalty structures. CEOs should ensure that collaboration agreements provide adequate operational control over key development decisions, particularly manufacturing and clinical program design, to protect the collaboration’s value.

CDMO partnerships. Given the specialized manufacturing requirements for ADC programs, CDMO relationships are strategic as well as operational. CEOs should cultivate CDMO partnerships as long-term relationships, with preference for CDMOs that invest in technology development and can grow with the company’s program portfolio.

This pharma business checklist provides a structured framework for auditing ADC operational readiness across the full development and commercial lifecycle.

Conclusion

Pharma CEO business operations for antibody drug conjugates demand mastery of manufacturing complexity, clinical strategy, competitive positioning, and commercial execution across oncology’s most dynamic therapeutic area. The CEO who builds operational excellence in ADC programs, from conjugation chemistry through payer contracting, positions the organization to deliver genuinely differentiated medicines to cancer patients with urgent unmet needs. In a competitive ADC landscape, operational quality is not just a hygiene factor; it is a source of sustainable competitive advantage.

Related Reading

For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.